196 related articles for article (PubMed ID: 24891448)
1. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
Jarry M; Lecointre C; Malleval C; Desrues L; Schouft MT; Lejoncour V; Liger F; Lyvinec G; Joseph B; Loaëc N; Meijer L; Honnorat J; Gandolfo P; Castel H
Neuro Oncol; 2014 Nov; 16(11):1484-98. PubMed ID: 24891448
[TBL] [Abstract][Full Text] [Related]
2. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
3. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
4. Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).
Schmitt L; Hoppe J; Cea-Medina P; Bruch PM; Krings KS; Lechtenberg I; Drießen D; Peter C; Bhatia S; Dietrich S; Stork B; Fritz G; Gohlke H; Müller TJJ; Wesselborg S
Cell Death Discov; 2024 Jun; 10(1):279. PubMed ID: 38862521
[TBL] [Abstract][Full Text] [Related]
5. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
7. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
[TBL] [Abstract][Full Text] [Related]
8. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.
Fan YZ; Zhao ZM; Fu JY; Chen CQ; Sun W
Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):414-22. PubMed ID: 20688607
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy.
Zhang C; Lundgren K; Yan Z; Arango ME; Price S; Huber A; Higgins J; Troche G; Skaptason J; Koudriakova T; Nonomiya J; Yang M; O'Connor P; Bender S; Los G; Lewis C; Jessen B
Mol Cancer Ther; 2008 Apr; 7(4):818-28. PubMed ID: 18413795
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
Juric V; Hudson L; Fay J; Richards CE; Jahns H; Verreault M; Bielle F; Idbaih A; Lamfers MLM; Hopkins AM; Rehm M; Murphy BM
Cell Death Dis; 2021 Aug; 12(8):763. PubMed ID: 34344865
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway.
Zheng J; Du W; Song LJ; Zhang R; Sun LG; Chen FG; Wei XT
World J Surg Oncol; 2014 Jul; 12():207. PubMed ID: 25022352
[TBL] [Abstract][Full Text] [Related]
13. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Byth KF; Thomas A; Hughes G; Forder C; McGregor A; Geh C; Oakes S; Green C; Walker M; Newcombe N; Green S; Growcott J; Barker A; Wilkinson RW
Mol Cancer Ther; 2009 Jul; 8(7):1856-66. PubMed ID: 19509270
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
15. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
[TBL] [Abstract][Full Text] [Related]
16. Triptolide inhibits proliferation and invasion of malignant glioma cells.
Zhang H; Zhu W; Su X; Wu S; Lin Y; Li J; Wang Y; Chen J; Zhou Y; Qiu P; Yan G; Zhao S; Hu J; Zhang J
J Neurooncol; 2012 Aug; 109(1):53-62. PubMed ID: 22562416
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
[TBL] [Abstract][Full Text] [Related]
18. A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.
Dai F; Chen Y; Song Y; Huang L; Zhai D; Dong Y; Lai L; Zhang T; Li D; Pang X; Liu M; Yi Z
PLoS One; 2012; 7(12):e52162. PubMed ID: 23300602
[TBL] [Abstract][Full Text] [Related]
19. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G
J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978
[TBL] [Abstract][Full Text] [Related]
20. Patrinia scabiosaefolia inhibits colorectal cancer growth through suppression of tumor angiogenesis.
Chen L; Liu L; Ye L; Shen A; Chen Y; Sferra TJ; Peng J
Oncol Rep; 2013 Sep; 30(3):1439-43. PubMed ID: 23820929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
